Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering. Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed ...

Accordingly, the stock price of the company’s shares decreases ... Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in ...

Shares of Purple Biotech Ltd (NASDAQ:PPBT ... The stock had previously closed at $4.69. Separately, HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target on shares of ...

The intraday chart, the last-five real-time quotes and sales data. Real-time stock quotes can be used to help inform investors when researching potential investment opportunities.

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

YTD Price Performance:-1.74% Average Trading Volume: 939,418 Technical Sentiment Consensus Rating: Sell Current Market Cap: $12.33M See more insights into PPBT stock on TipRanks’ Stock Analysis ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT ... Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the ...